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C3H/HeN mice administered BCG followed by lipo- helper factor and the CF are distinct molecular entities. We 
polysaccharide 14 days  later  released  into  their  serum  a further show that  the helper factor co-purifies with a soluble 
cytotoxic  factor  for  tumor cells and  a  factor  that  restored factor that enhances the proliferative response of thymocytes 
the anti-SRBC plaque-forming cell response of nude to PHA and is probably identical with macrophage-derived 
mouse spleen cells (helper activity). Gel filtration of lymphocyte activation factor (LAF; Interleukin 1 (IL l)).3 
serum  containing  the  cytotoxic  and  the  helper activities 
indicated  hat  bo h factors  exhibited  an  apparent  m.w. MATERIALS AND  METHODS 
of  125,000 to 150,000.  The  helper activity was also found 
at  lower  m.w. (60,000 and  13,000) suggesting the possi- 
bility  that this factor existed in  aggregated  forms. Gel 
filtration of ammonium sulfate (40 to 60% saturation) 
precipitated  serum in a high ionic  strength  buffer (1.6 M 
NaCl) resulted in shifts in the apparent m.w. of both 
factors. The cytotoxic factor now exhibited a m.w. of 
55,000. The helper activity eluted  with  an  apparent  m.w. 
of  13,000,  and thus was clearly  separated  from  the cyto- 
toxic  factor.  The  helper activity was further  shown to 
co-elute  with  macrophage-derived  lymphocyte activat- 
ing factor (LAF). This as well as other  data  represent the 
first  demonstration  of in vivo produced LAF. 
Administration of lipopolysaccharide (LPS) from Gram-neg- 
ative bacteria to bacillus Calmette-Guerin-(BCG)’ infected 
mice induces the release into the serum of a number of biolog- 
ically active soluble products, including colony-stimulating fac- 
tor (l), interferon (2),  tumor necrosis factor (TNF) (3-6), and 
PFC helper factor (3). In addition, the serum exhibits marked 
cytotoxic effects on tumor cells grown in culture (4, 7,8).  This 
cytotoxic  effect has generally been considered to represent an 
in vitro assay for TNF (7, 8). Recently, Hoffmann et al. (3, 6) 
reported that  the PFC helper factor and TNF co-purified after 
ammonium sulfate precipitation, gel filtration, and polyacryl- 
amide gel electrophoresis, suggesting that both the helper and 
cytotoxic activities might be mediated by the same molecular 
species. In the course of our investigations on the isolation and 
purification of LPS-induced cytotoxic factor (CF) for tumor 
cells, we also observed that serum from  BCG-primed and LPS- 
treated mice contained not only tumoricidal activity but also 
PFC helper activity. In this report, we demonstrate that  the 
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Mice. C3H/HeJ mice  were obtained from The Jackson Lab- 
oratory, Bar Harbor, Maine, C3H/HeN mice and C57BL/ 
lOScN nude mice  were  provided  by the Division of Research 
Resources, National Institutes of Health, Bethesda, Md., and 
BALB/C nude mice  were purchased from ARS Sprague-Daw- 
ley,  Madison, Wis. Male and female mice 6 to 15  weeks of age 
were  used in all experiments. 
Bacillus Calmette-Gukrin. Mycobacterium bovis, strain BCG 
(Phipps substrain TMC No. 1029), was obtained from the 
Trudeau Mycobacterial Collection, Saranac Lake,  N. Y. 
Lipopolysaccharide. Escherichia coli,  K-235 LPS was pre- 
pared by the phenol-water extraction method of McIntire et al. 
(9). 
Generation of BCG-LPS serum. C3H/HeN mice were in- 
jected i.v. with 2 X IO6 colony-forming units of living BCG. Two 
weeks later the mice  were injected i.v. with 10 pg  of LPS. The 
mice  were exsanguinated 2 hr later,  the serum was sterilized by 
filtration and stored at -20°C until further use (BCG-LPS 
serum). Control sera from mice injected with BCG (BCG se- 
rum) or LPS without prior BCG infection (LPS serum) were 
similarly prepared. 
Cytotoxic factor assay. Tumor cells (mouse L cells strain 
929)  were  seeded  in  16-mm culture wells (Costar No. 3524) (4 
X lo4 cells/well) and labeled in 0.5 ml Eagle’s minimal essential 
medium (EMEM) with 25 mM HEPES (see Abbreviations) 
buffer, 5% heat-inactivated (30 min, 56°C) fetal calf serum 
(FCS), and 0.5 p l / d  [3H]TdR fmeth~l-(~H)-thymidine, sp. act. 
1.9 Ci/mmol, Schwan/Mann, Orangeburg, N. Y.) for 18 to 24 
hr. Tumor cell monolayers were washed twice after labeling 
and incubated with 1 ml of Dulbecco’s  modified  Eagle’s  minimal 
essential medium (DMEM) HG  (4.5 g glucose/liter; 2 g 
NaHCOJiter, 10% heat-inactivated FCS, and 50 pg gentamy- 
c in /d)  with different dilutions of BCG-LPS and control serum. 
Labeled tumor cell monolayers lysed  with 0.5% sodium  dodecyl 
sulfate in water were  used to estimate total incorporated counts. 
Cytotoxicity  was determined by  measuring release of incorpo- 
rated [3H]TdR from prelabeled tumor cells in duplicate cul- 
tures. 
‘ A revised nomenclature for lymphocyte-activating factor (LAF) 
was proposed at  the recent Second International Lymphokine Work- 
shop  (Ermatingen, Switzerland, May 27-31, 1979). The revised name 
for LAF is Interleukin 1. To avoid confusion, the term IL 1 will be 
initially assimilated into the literature by using both acronyms as 
follows: LAF (IL 1). With time, the term LAF will  be deleted. 
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PFC helper factor  assay. Dilutions of BCG-LPS and control 
sera were assayed for their ability to restore the in uitro anti- 
SRBC PFC response of nude mouse spleen cells as previously 
described (lo), with the exception that  the cells  were cultured 
in the presence of 1% normal mouse serum rather  than FCS. 
Thymocyteproliferatn  assay. Dilutions of BCG-LPS serum 
and control serum were assayed for their ability to enhance the 
proliferative response of C3H/HeJ mouse thymocytes to 1.0 
pg/ml PHA as described previously (10). 
Ammonium  sulfate precipitation of serum. Ten milliliters of 
both BCG-LPS and control sera were precipitated by 
(NH4),S04. Sufficient (NH&S04 was  slowly added to  the stir- 
ring serum samples at 4°C to achieve 40% (N&)2S04 saturation. 
The precipitate was then  stirred for 1 hr, followed  by centrifu- 
gation at 10,000 X G for 15 min. The precipitate was  dissolved 
in pH 7.5 (4°C) Tris-buffered saline (0.05 M Tris, 0.1 M NaCl). 
The precipitation, centrifugation, and redissolving of the pre- 
cipitate were then repeated with the supernatant  to prepare 40 
to 60%, 60 to 808, and 80 to 100% (NH4)2S04 saturation precip- 
itated samples. All of the samples were dialyzed extensively 
against Tris-buffered saline. 
Gel filtration. Up to 10 ml of either unfractionated or am- 
monium sulfate-precipitated serum samples were subjected to 
gel filtration on a 2.5 x 90  cm calibrated Sephacryl S-200 column 
that  had been equilibrated in  pH 7.5 (4°C) Tris (0.05 M) buffer 
containing either 0.1 M or 1.6 M NaC1. All chromatography was 
performed at 4°C by using reverse flow at a flow rate of 
approximately 20 ml/hr. Fractions of 2.5 to 2.8 ml were col- 
lected. Each fraction was individually and extensively  dialyzed 
against tissue culture medium. Normal mouse serum was added 
to each fraction to a concentration of 1%, and the fractions were 
sterilized by filtration and assayed for CF, PFC helper activity, 
and thymocyte mitogenic activity as described above. 
Protein  determination. Protein content of BCG-LPS serum, 
LPS serum, and partially purified fractions were determined by 
using the Bio-Rad protein assay kit (Bio-Rad, Richmond, 
Calif. ) . 
RESULTS 
Serum from  BCG-infected  mice  challenged with LPS (BCG- 
LPS serum) and control sera (LPS serum and BCG serum) 
were tested for their cytotoxic and PFC helper activity. The 
results of a representative experiment are shown in Figure 1. 
The cytotoxic activity of BCG-LPS serum for murine tumor 
cell targets was observed at dilutions ranging from lo-' to 5 X 
High tumoricidal activity was consistently found at a 
dilution of 1:lOO. The BCG-LPS serum exhibited a similar dose- 
dependent enhancing effect on the  PFC response. Significant 
helper activity was detected at dilutions as low as 1:1280. The 
controls consisting of serum from either  LPS- (shown) or  BCG- 
(not shown) treated mice  failed to exhibit either cytotoxic or 
PFC helper activity. 
In order to separate the cytotoxic activity from the PFC- 
promoting activity (helper factor), BCG-LPS and LPS sera 
were subjected to gel filtration on a Sephacryl S-200 column, 
and the fractions were assayed for CF and helper factor (Fig. 
2). CF consistently eluted as a single peak with  maximal activity 
at a m.w. of approximately 150,000. In this experiment, the 
helper activity eluted as one major peak with an  apparent m.w. 
of 60,000 and two minor peaks with apparent m.w.  of approxi- 
mately 125,000 and 13,000. In other experiments, the principal 
helper activity peak was observed to co-elute with CF in the 
m.w. range of 125,000 to 150,000. Thus, although the PFC 
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Figure 1. Dose responses of BCG-LPS  serum  and  control Serum for 
tumor cytotoxicity and PFC helper activity. Tumor cytotoxicity was 
estimated by [3H] TdR release of labeled L 929 cells after 48 hr of 
incubation  in  different  dilutions of BCG-LPS serum (closed  circles) or 
control  serum (open  circles) (total incorporated  cpm = 45 X lo3) (solid 
lines). Plaque-forming cell helper activity was determined  in the anti- 
SRBC  plaque  assay  with  nude  mouse spleen cells by  adding  different 
dilutions of BCG-LPS serum (closed  circles) or control serum (open 
circles) to the cultures at day 0 (dashed  lines). 
helper factor may elute in the m.w. range of CF (125,000 to 
150,000), these data suggest that  the helper factor exists in 
aggregated forms, and that separation of the helper factor from 
CF by  gel filtration is dependent on  the deaggregation of the 
helper factor. 
In order to concentrate larger volumes of serum in prepara- 
tion for gel filtration, the proteins in the BCG-LPS and control 
sera were precipitated with ammonium sulfate. The CF and 
helper activities present in the sequential ammonium sulfate 
precipitates are shown in Figure 3. The results show that 
approximately 50% of the precipitated protein and virtually 
100% of the CF and helper activities are present in the 40 to 
60% ammonium sulfate saturation precipitate. The precipitates 
of the control serum from LPS-treated mice exhibited neither 
CF nor helper activity. Subsequent ammonium sulfate precip- 
itation experiments demonstrated that most of the CF and 
helper activities were precipitated between 45 to 50% ammo- 
nium sulfate saturation (data not shown). When this latter 
precipitated fraction was subjected to gel filtration under con- 
ditions of high ionic strength, the elution profiles of CF and 
helper factor shown  in Figure 4 were obtained. Panel A shows 
that under these chromatographic conditions, CF elutes at an 
apparent m.w. of 55,000, whereas the helper factor (Panel  B) 
now eluted at a m.w.  of 13,000. No helper activity was  found in 
higher m.w. fraction pools. Thus, under these conditions, both 
CF and the helper factor were found to elute as single peaks 
with distinct m.w. Because of the similarity in the m.w.  of the 
helper factor and that reported for LAF (IL 1) (11-13), which 
also has been shown to enhance the antibody response of T 
cell-deficient  mouse spleen cells (14-X), the lower m.w. frac- 
tions containing the helper activity were dso assayed for their 
ability to enhance thymocyte proliferation in a standard LAF 
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Figure 2. Sephacryl S-200 chromatography  of BCG-LPS serum  and 
control  serum. Two milliliters of unfractionated BCG-LPS serum (solid 
line) or control  serum (dashed line) were subjected to Sephacryl S-200 
gel  filtration. The column was equilibrated  and eluted with Tris buffer 
(pH 7.5) containing 0.1 M sodium chloride. Fractions of 2.5 ml were 
collected. Tumor cytotoxic activity (Panel A )  and  PFC  helper activity 
(Panel B) were estimated as described in Materials and Methods. 
(IL 1) assay (Panel C). A comparison of Panels B and C 
demonstrate that  the fractions containing helper activity are 
also mitogenic for mouse thymocytes, maximal activity in both 
assays appearing in the identical fraction. As seen previously, 
none of the fractions from the control LPS serum exhibited CF, 
PFC helper factor, or thymocyte mitogenic activity. 
In addition  to the negative results  obtained with the control 
serum  (LPS-induced serum), we tested the possibility that  the 
PFC helper activity in BCG-LPS serum fractions was due  to a 
direct LPS effect.  Accordingly, we compared the helper  activity 
of a pool  of  low molecular BCG-LPS serum fractions containing 
LAF (IL 1) and  LPS itself in  cultures containing LPS-responsive 
and nonresponsive nude mouse spleen cells (Fig. 5) .  The  data 
in Panel  A  demonstrates that  the  PFC response of both  LPS 
responsive (BALB/C) and nonresponsive (BL/lOScN) nude 
mouse spleen cells is restored by the addition of partially 
purified serum-derived helper factor from BCG- and LPS- 
treated mice. In contrast, the  data in  Panel  B shows that  the 
PFC response of the LPS-responsive nude mouse spleen cells, 
but  not the nonresponsive nude mouse spleen cells, is enhanced 
by the addition of LPS  to  the cultures. 
DISCUSSION 
Recently, Hoffmann et al. (3) reported that  serum from BCG- 
infected mice challenged with LPS contained tumor necrosis 
factor  and  a PFC helper factor, and  that a partially purified 
preparation contained both activities. The m.w. described for 
both activities was reported to be approximately 150,000. We 
have similarly found that cytotoxic factor and helper activity 
to exhibit similar apparent m.w. (125,000 to 150,000) when 
unfractionated serum is chromatographed under conditions 
that do not favor molecular deaggregation (data  not shown). 
However, when the BCG-LPS  serum  was first precipitated with 
ammonium sulfate  and then subjected to gel filtration  in high 
ionic strength buffer, the cytotoxic serum factor was clearly 
separable from the helper activity (Fig. 4). Thus,  the helper 
factor in LPS-induced serum from BCG-treated mice appears 
to be a distinct molecular species from the CF. The  apparent 
m.w. of the  CF (55,000) obtained  in gel filtration experiments 
with the high ionic strength buffer is in close agreement with 
the m.w. estimate (50,000) for a  rabbit cytotoxic factor (desig- 
nated TNF by the  authors) (8). Recent observations from our 
laboratory show that  the activated macrophage is the cellular 
source for CF (D. Mannel and S. Mergenhagen, manuscript in 
preparation) as  it was proposed for TNF (4). Our observation 
that the PFC helper activity in BCG-LPS serum exhibits a 
m.w.  of 13,000 is of interest, in view  of the  fact  that  the principal 
macrophage-derived helper factor produced in vitro after stim- 
ulation with a variety of agents, including LPS, also exhibits a 
similar m.w. (15, 16). Moreover, similar to what has been 
observed with in vitro-produced macrophage-derived helper 
factor (15, 16), the factor  present in LPS-induced serum from 
BCG-infected mice also exhibits the capacity to enhance the 
thymocyte proliferative response (Fig. 4). Thus, by a number of 
criteria, including: 1) the m.w., 2) biologic activities, 3) inductive 
stimulant, and 4) presumptive cell of origin (the activated 
macrophage (13,14,16), the  PFC helper factor present in  BCG- 
LPS serum is presumably identical to LAF (IL 1). This repre- 
sents the fmst demonstration of in uiuo-produced LAF (IL 1) 
activity. 
Numerous reports have shown that activated macrophages 
as well as tumor-specific cytotoxic T cells provide important 
host defense mechanisms against tumors (17). Furthermore, 
recent experiments indicate that  LPS may serve to enhance 
c 
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Figure 3. Ammonium sulfate precipitation  of BCG-LPS serum  and 
control  serum. Ten milliliters of BCG-LPS  serum (open bars) or control 
serum (solid  bars) were  precipitated  with  ammonium sulfate in  increas- 
ing increments of concentration. For each fraction, the amount of 
precipitated protein was determined (Panel A ) ,  the tumor cytotoxic 
activity (in 1:lOOO dilution, total incorporated  cpm = 30 X lo3) (Panel 
B) and  PFC  helper activity (in 1:320 dilution) (Panel C )  were estimated 
as described  in Materials and Methods. 
19801 LPS-INDUCED SERUM FACTORS IN BCG-INFECTED MICE 1109 
both the nonspecific and specific anti-tumor host defense mech- 
anisms (18,19). For example, Russel et al. (18) have shown that 
primed macrophages from tumors can be triggered to become 
cytotoxic with very low concentrations of LPS in  vitro. Simi- 
larly, Berendt et al. (19, 20) have shown that administration of 
LPS to tumor-bearing mice initiates antigen-specific T cell- 
dependent regression of the tumors. Because the activation of 
antigen-specific cytotoxic T cells in this latter system as well as 
in numerous other in vitro systems has been shown to be 
macrophage dependent  (19,20), the LPS-activated macrophage 
is presumably crucial to the antigen-specific as well as the 
nonspecific mechanisms of tumor immunity. Thus,  LPS  appar- 
ently exhibits a bimodal anti-tumor effect; being involved in 
macrophage-activation processes that culminate in enhanced 
specific and nonspecXc  host defense mechanisms. 
In this regard, it is of inter& that we were able to identify 
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Figure4. Sephacryl S-200 chromatography of ammonium sulfate 
precipitated BCG-LPS serum. The 45 to 50% ammonium sulfate pre- 
cipitate from 10 ml of BCG-LPS serum was subjected to Sephacryl S- 
200 gel filtration on a 2.5- x 90-cm column. The column was equilibrated 
and  eluted with Tris buffer (pH 7.5) containing 1.6 M sodium chloride. 
Fractions of 2.7 ml were collected. Tumor cytotoxic activity (Panel A ) ,  
PFC helper activity (Panel B) ,  and thymocyte proliferative activity 
(Panel C )  were assayed as described in Materials  and Methods. For 
the PFC helper activity, pools of 10 fractions each were assayed first 
and then individual fractions were tested in the region where the 
activity was located. 
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Figure 5. Comparison of LPS responsive and nonresponsive nude 
mouse spleen cells to the PFC helper activity of BCG-LPS serum 
derived LAF (IL 1) and LPS. The fractions which had PFC helper 
activity and LAF (IL 1) activity after ammonium sulfate precipitation 
and Sephacryl S-200 chromatography were pooled and assayed in 
different dilutions for their ability to restore the anti-SRC plaque- 
forming response of LPS responsive (BALB/C) nude mouse spleen 
cells (open circles) and  LPS nonresponsive (BL/lOScN) nude mouse 
spleen cells (closed circles) (Panel A).  In parallel, the ability of E. coli 
K 235 LPS  to restore the plaque-forming response was determined in 
the same assay with both mouse strains (Panel B ) .  
and separate two putative macrophage-derived soluble products 
in the LPS-induced serum from BCG-infected mice that might 
provide the mediators for the nonspecific and specific LPS 
effects. CF would presumably be involved in a nonspecific 
tumoricidal (tumor necrosis) effect. This nonspecific effect is 
apparently T cell independent,  in that  CF is produced in nude 
mice and the tumor necrosis effect of LPS can  be observed in 
tumor-bearing T cell-deficient mice (19). In contrast, we would 
suggest that LAF (IL l), which we were detecting as  an  enhan- 
cer of the  PFC response, might also be involved in the induction 
of a T cell-dependent antigen-specific anti-tumor response. This 
hypothesis is supported by the observation that highly purified 
LAF (IL 1) is capable of replacing the requirement for macro- 
phages during the in vitro induction of alloantigen specific 
cytotoxic T cells (21). These data  are totally consistent with 
the observations of Berendt et al. (19), who have shown that 
LPS-induced tumor regression is dependent upon: 1) the im- 
munogenicity of the tumor, and 2) collaborative interactions 
between macrophages and T cells. 
Further characterization of the immunologically active fac- 
tors in BCG-LPS serum and  their application to in vivo exper- 
iments should help to clarify the relationship between the 
specific and nonspecific anti-tumor effects of LPS-activated 
macrophages. 
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